Trinity Biotech's CGM+ System Advances Diabetes Management with Fingerstick-Free Technology

Trinity Biotech has made significant strides in the continuous glucose monitoring (CGM) market with its innovative CGM+ system, designed to operate without fingerstick calibration for up to 15 days. This development marks a crucial milestone in the company's strategic pivot towards personal diabetes management solutions.

Breakthrough in Glucose Monitoring Technology

The CGM+ system represents a notable advancement in diabetes care, offering accurate glucose readings throughout its 15-day lifespan without the need for traditional fingerstick calibrations. This feature aligns Trinity Biotech's offering with industry leaders while introducing a unique product architecture that promises enhanced affordability, reusability, and sustainability.

John Gillard, CEO of Trinity Biotech, emphasized the significance of this achievement, stating, "This milestone represents the most significant technical achievement since we began redevelopment of our acquired CGM technology." He further explained that the elimination of fingerstick calibration was accomplished through "a combination of sensor design modifications, refined signal processing, and proprietary enhancements to sensor operation."

Multi-Functional Wearable Design

Beyond glucose monitoring, the CGM+ system is designed as a comprehensive health monitoring platform. Trinity Biotech plans to incorporate modular sensors capable of tracking additional vital signs and activities, including:

• Pulse rate
• Sleep patterns
• Step count
• Heart activity
• Body temperature

This multi-functional approach positions the CGM+ as a versatile wearable device, potentially offering users a more holistic view of their health metrics in a single, integrated system.

Market Potential and Launch Timeline

Trinity Biotech is targeting a sizable market opportunity with its CGM+ system. The company estimates the global CGM market at $13 billion, with projections suggesting growth to approximately $28 billion by the end of the decade. This market forms part of the broader wearable device industry, which continues to expand rapidly.

Following the successful completion of its pre-pivotal trial focusing on the glucose sensor component, Trinity Biotech has set an ambitious timeline for bringing the CGM+ system to market. The company is aiming for a commercial launch in mid-2026, signaling confidence in its development progress and regulatory pathway.

As the diabetes management landscape continues to evolve, Trinity Biotech's CGM+ system represents a promising advancement in wearable health technology, potentially offering patients a more convenient and comprehensive solution for monitoring their condition.